Pyrazolam

Pyrazolam is a novel depressant substance belonging to the benzodiazepine class. It was originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s. Subsequently, it was “rediscovered” and sold as a research chemical starting in 2012.

Here are some key points about pyrazolam:

1. Chemical Structure:
   • Systematic Name: 8-bromo-1-methyl-6-(pyridin-2-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine.
   • Class Membership: Depressant.
   • Subjective Effects: Pyrazolam produces sedation, anxiety suppression, muscle relaxation, disinhibition, and mild euphoria.
   • Recreational Use: It is less euphoric than other benzodiazepines, limiting its recreational appeal.
   • Caution: Abrupt discontinuation of benzodiazepines can be dangerous, so gradual tapering is recommended.
2. Dosage (Oral):
   • Threshold: 0.5 mg.
   • Common: 1 – 2 mg.
   • Strong: 2 – 3 mg.
   • Heavy: 3 – 4 mg.
   • Duration: Approximately 5 – 8 hours.
   • Always start with lower doses due to individual variations in weight, tolerance, and sensitivity.
3. Toxicity and Harm Potential:
   • Tolerance and Addiction: Benzodiazepines can lead to mental and physical dependence with continued use.
   • Overdose: Combining benzodiazepines with other depressants (such as opiates, alcohol, or GABAergic substances) can be dangerous.
   • Harm Reduction: Use harm reduction practices when using this substance.
4. History and Culture:
   • Pyrazolam was first developed by Hoffman-La Roche in the 1970s and later gained attention as a research chemical.
   • The first official reports of pyrazolam came from Finland in 2011 and the UK in 2012.

Remember that this information is for educational purposes only, and if you have any specific concerns or questions, it’s essential to verify with other reliable sources.